We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
1
Total approvals
Agencies
Regulatory bodies
Founded
1975
No trial phase data available
No trial data available
SFDA
Saudi Food and Drug Authority
- Mikart and Nano PharmaSolutions reported positive interim Phase 1 safety and pharmacokinetic data for NT-301, a proprietary powder nasal spray targeting Parkinson's disease OFF episodes. - The nanodrug delivery system demonstrated dose-proportional exposure and rapid absorption with Tmax of approximately 20 minutes in healthy volunteers across 1-3 mg doses. - NT-301 utilizes NanoTransformer® technology, a patented platform that enhances drug solubility and bioavailability through nano-coating of active pharmaceutical ingredients. - Companies are expanding manufacturing capabilities for the NanoTransformer® platform to meet anticipated demand as clinical development progresses.
